News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Merck & Co., Inc. CEO: Acquisitions are Key Priority for 2009
January 8, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Merck & Co.'s (MRK 29.39, -0.10, -0.3%) leader said the drug maker has the resources to make significant acquisitions, but if the company doesn't make big purchases it will return cash to shareholders through dividends or share buybacks.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Merck & Co.
MORE ON THIS TOPIC
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
February 11, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Earnings
Novartis Sticks With M&A Strategy of Building Early Pipeline, Searching for Near-Launches
February 4, 2026
·
2 min read
·
Tristan Manalac